Thyroid cancer and co-occurring RET mutations in Hirschsprung disease

Endocrine-Related Cancer

Volumn 20, Issue 4, 2013, Pages 595-602

  Virtanen, Valtter B ^a   Pukkala, Eero ^b,c   Kivisaari, Reetta ^d   Salo, Perttu P ^e   Koivusalo, Antti ^a   Arola, Johanna ^f   Miettinen, Päivi J ^a,g   Rintala, Risto J ^a   Perola, Markus ^e,h   Pakarinen, Mikko P ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b FINNISH CANCER REGISTRY   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f UNIVERSITY OF HELSINKI   (Finland)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h UNIVERSITY OF TARTU   (Estonia)

Author keywords

Hirschsprung disease; Multiple endocrine neoplasia; Oncology; Thyroid cancer

Indexed keywords

ADULT; AGED; ARTICLE; CALCITONIN BLOOD LEVEL; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; CLINICAL ASSESSMENT; CYTOLOGY; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HIRSCHSPRUNG DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONCOGENE RET; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TERTIARY HEALTH CARE; THYROID CANCER; THYROID MEDULLARY CARCINOMA; ULTRASOUND;

HIRSCHSPRUNG DISEASE; MULTIPLE ENDOCRINE NEOPLASIA; ONCOLOGY; THYROID CANCER;

ADULT; AGED; CALCITONIN; EXONS; FEMALE; HIRSCHSPRUNG DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS C-RET; THYROID GLAND; THYROID NEOPLASMS;

EID: 84882786665     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-13-0082     Document Type: Article

References (37)

1. Amiel J, Sproat-Emison E, Garcia-Barcelo M, Lantieri F, Burzynski G, Borrego S, Pelet A, Arnold S, Miao X, Griseri P et al. 2008 Hirschsprung disease, associated syndromes and genetics: a review. Journal of Medical Genetics 45 1-14. (doi:10.1136/jmg.2007.053959)
2. Arighi E, Popsueva A, Degl'Innocenti D, Borrello MG, Carniti C, Perälä NM, Pierotti MA & Sariola H 2004 Biological effects of the dual phenotypic Janus mutation of ret cosegregating with both multiple endocrine neoplasia type 2 and Hirschsprung's disease. Molecular Endocrinology 18 1004-1017. (doi:10.1210/me.2003-0173)
3. Attié T, Pelet A, Edery P, Eng C, Mulligan LM, Amiel J, Boutrand L, Beldjord C, Nihoul-Fékété C, Munnich A et al. 1995 Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. Human Molecular Genetics 4 1381-1386. (doi:10.1093/hmg/4.8.1381)
4. Borrego S, Sáez ME, Ruiz A, Gimm O, López-Alonso M, Antiñolo G & Eng C 1999 Specific polymorphisms in the RET proto-oncogene are overrepresented in patients with Hirschsprung disease and may represent loci modifying phenotypic expression. Journal of Medical Genetics 36 771-774. (doi:10.1136/jmg.36.10.771)
5. Borst MJ, VanCamp JM, Peacock ML & Decker RA 1995 Mutational analysis of multiple endocrine neoplasia type 2A associated with Hirschsprung's disease. Surgery 117 386-391. (doi:10.1016/S0039-6060(05)80057-1)
6. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, Conte-Devolx B, Falchetti A, Gheri RG, Libroia A et al. 2001 Guidelines for diagnosis and therapy of MEN type 1 and type 2. Journal of Clinical Endocrinology and Metabolism 86 5658-5671. (doi:10.1210/jc.86.12.5658)
7. Bütter A, Gagné J, Al-Jazaeri A, Emran MA, Deal C & St-Vil D 2007 Prophylactic thyroidectomy in pediatric carriers of multiple endocrine neoplasia type 2A or familial medullary thyroid carcinoma: mutation in C620 is associated with Hirschsprung's disease. Journal of Pediatric Surgery 42 203-206. (doi:10.1016/j.jpedsurg.2006.09.019)
8. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE, Wells SA Jr, Goodfellow PJ & Donis-Keller H 1994 Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. PNAS 91 1579-1583. (doi:10.1073/pnas.91.4. 1579)
9. Decker RA, Peacock ML & Watson P 1998 Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. Human Molecular Genetics 7 129-134. (doi:10.1093/hmg/7.1.129)
10. De Groot JW, Sijmons RH, Links TP, Plukker JT & Hofstra RM 2005 Medullary thyroid cancer in a patient with Hirschsprung disease with a C609Y germline RET-mutation. Journal of Pediatric Gastroenterology and Nutrition 40 226-229. (doi:10.1097/00005176-200502000-00028)
11. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC, Howe JR, Moley JF, Goodfellow P & Wells SA Jr 1993 Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Human Molecular Genetics 2 851-856. (doi:10.1093/hmg/2.7.851)
12. Dvoráková S, Dvoráková K, Malíková M, Skába R, Vlcek P & Bendlová B 2005 A novel Czech kindred with familial medullary thyroid carcinoma and Hirschsprung's disease. Journal of Pediatric Surgery 40 e1-e6. (doi:10.1016/j.jpedsurg.2005.03.031)
13. Eng C 1999 RET proto-oncogene in the development of human cancer. Journal of Clinical Oncology 17 380-393. (Pubitemid 29022417)
14. Erlic Z, Hoffmann MM, Sullivan M, Franke G, Peczkowska M, Harsch I, Schott M, Gabbert HE, Valimäki M, Preuss SF et al. 2010 Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. Journal of Clinical Endocrinology and Metabolism 95 308-313. (doi:10.1210/jc.2009-1728)
15. Fernández RM, Antiñolo G, Eng C & Borrego S 2003 The RET C620S mutation causes multiple endocrine neoplasia type 2A (MEN2A) but not Hirschsprung disease (HSCR) in a family cosegregating both phenotypes. Human Mutation 22 412-415. (doi:10.1002/humu.10273)
16. Fialkowski EA, DeBenedetti MK, Moley JF & Bachrach B 2008 RET proto-oncogene testing in infants presenting with Hirschsprung disease identifies 2 new multiple endocrine neoplasia 2A kindreds. Journal of Pediatric Surgery 43 188-190. (doi:10.1016/j.jpedsurg.2007.09.043)
17. Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T, Rondot S, Höppner W & Raue F 2006 Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. European Journal of Endocrinology 155 229-236. (doi:10.1530/eje.1.02216)
18. Frank-Raue K, Machens A, Scheuba C, Niederle B, Dralle H & Raue F 2008 Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Clinical Endocrinology 69 259-263. (doi:10.1111/j.1365-2265.2008.03215.x)
19. Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I, Toledo SP, Toledo RA, Tavares MR, Alevizaki M et al. 2011 Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Human Mutation 32 51-58. (doi:10.1002/humu.21385)
20. Gariepy CE 2003 Genetic basis of Hirschsprung disease: implications in clinical practice. Molecular Genetics and Metabolism 80 66-73. (doi:10.1016/j.ymgme.2003.08.007)
21. Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Porta G, Fusco A & Vecchio G 1990 PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 60 557-563. (doi:10.1016/0092-8674(90) 90659-3)
22. Hansford JR & Mulligan LM 2000 Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. Journal of Medical Genetics 37 817-827. (doi:10.1136/jmg.37.11.817)
23. Hofstra RM, Landsvater RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y, Pasini B, Höppener JW, van Amstel HK, Romeo G et al. 1994 A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367 375-376. (doi:10.1038/367375a0)
24. Le Douarin N & Kalcheim C 1999 The autonomic nervous system and the endocrine cells of neural crest origin. Origin and migratory pathways followed by distinct autonomic progenitors. In The Neural Crest, 2nd edn, pp 198-207. Cambridge, UK: Cambridge University Press.
25. Martucciello G, Ceccherini I, Lerone M & Jasonni V 2000 Pathogenesis of Hirschsprung's disease. Journal of Pediatric Surgery 35 1017-1025. (doi:10.1053/jpsu.2000.7763)
26. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E, Love DR, Mole SE, Moore JK, Papi L et al. 1993 Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363 458-460. (doi:10.1038/363458a0)
27. Mulligan LM, Eng C, Attié T, Lyonnet S, Marsh DJ, Hyland VJ, Robinson BG, Frilling A, Verellen-Dumoulin C, Safar A et al. 1994a Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. Human Molecular Genetics 3 2163-2167. (doi:10.1093/hmg/3.12.2163)
28. Mulligan LM, Eng C, Healey CS, Clayton D, Kwok JB, Gardner E, Ponder MA, Frilling A, Jackson CE, Lehnert H et al. 1994b Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC. Nature Genetics 6 70-74. (doi:10.1038/ng0194-70)
29. Nishikawa M, Murakumo Y, Imai T, Kawai K, Nagaya M, Funahashi H, Nakao A & Takahashi M 2003 Cys611Ser mutation in RET proto-oncogene in a kindred with medullary thyroid carcinoma and Hirschsprung's disease. European Journal of Human Genetics 11 364-368. (doi:10.1038/sj.ejhg.5200971)
30. Pakarinen MP, Rintala RJ, Koivusalo A, HeikkinenM, Lindahl H& Pukkala E 2005 Increased incidence of medullary thyroid carcinoma in patients treated for Hirschsprung's disease. Journal of Pediatric Surgery 40 1532-1534. (doi:10.1016/j.jpedsurg.2005.05.041)
31. Pasini B, Rossi R, Ambrosio MR, Zatelli MC, Gullo M, Gobbo M, Collini P, Aiello A, Pansini G, Trasforini G et al. 2002 RET mutation profile and variable clinical manifestations in a family with multiple endocrine neoplasia type 2A and Hirschsprung's disease. Surgery 131 373-381. (doi:10.1067/msy.2002.121093)
32. Pukkala E 2011 Biobanks and registers in epidemiologic research on cancer. Methods in Molecular Biology 675 127-164. (doi:10.1007/978-1-59745-423- 0-5)
33. Romeo G, Ceccherini I, Celli J, Priolo M, Betsos N, Bonardi G, Seri M, Yin L, Lerone M, Jasonni V et al. 1998 Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. Journal of Internal Medicine 243 515-520. (doi:10.1046/j.1365-2796.1998.00332.x)
34. Sijmons RH, Hofstra RM, Wijburg FA, Links TP, Zwierstra RP, Vermey A, Aronson DC, Tan-Sindhunata G, Brouwers-Smalbraak GJ, Maas SM et al. 1998 Oncological implications of RET gene mutations in Hirschsprung's disease. Gut 43 542-547. (doi:10.1136/gut.43.4.542)
35. Skába R, Dvoráková S, Václaví ková E, Vlcek P, Frantlová M & Bendlová B 2006 The risk of medullary thyroid carcinoma in patients with Hirschsprung's disease. Pediatric Surgery International 22 991-995. (doi:10.1007/s00383-006-1785-6)
36. Teppo L, Pukkala E & Lehtonen M 1994 Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncologica 33 365-369. (doi:10.3109/02841869409098430)
37. Toledo RA, Wagner SM, Coutinho FL, Lourenço DM Jr, Azevedo JA, Longuini VC, Reis MT, Siqueira SA, Lucon AM, Tavares MR et al. 2010 High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the RET protooncogene. Journal of Clinical Endocrinology and Metabolism 95 1318-1327. (doi:10.1210/jc.2009-1355)